Advertisement
Advertisement

AMRX

AMRX logo

Amneal Pharmaceuticals, Inc. Class A Common Stock

17.29
USD
Sponsored
+0.63
+3.78%
Jun 24, 12:21 UTC -4
Open

AMRX Earnings Reports

Positive Surprise Ratio

AMRX beat 28 of 42 last estimates.

67%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$775.77M
/
$0.22
Implied change from Q1 26 (Revenue/ EPS)
+7.37%
/
-18.52%
Implied change from Q2 25 (Revenue/ EPS)
+7.08%
/
-12.00%

Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Apr 22, 2026, AMRX reported earnings of 0.27 USD per share (EPS) for Q1 26, beating the estimate of 0.17 USD, resulting in a 55.71% surprise. Revenue reached 722.52 million, compared to an expected 729.58 million, with a -0.97% difference. The market reacted with a -1.54% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.22 USD, with revenue projected to reach 775.77 million USD, implying an decrease of -18.52% EPS, and increase of 7.37% in Revenue from the last quarter.
FAQ
For Q1 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.27, beating estimates by 55.71%, and revenue of $722.52M, -0.97% below expectations.
The stock price moved down -1.54%, changed from $13.02 before the earnings release to $12.82 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 6 analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.22 and revenue of $775.77M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement